ValuEngine lowered shares of Amedica (NASDAQ:AMDA) from a hold rating to a sell rating in a report released on Friday.
A number of other equities research analysts have also recently commented on AMDA. Maxim Group cut Amedica from a buy rating to a hold rating in a research note on Monday, September 25th. Ladenburg Thalmann Financial Services cut Amedica from a buy rating to a neutral rating in a research note on Monday, November 27th.
Shares of Amedica (AMDA) opened at $3.33 on Friday. Amedica has a 12-month low of $2.95 and a 12-month high of $9.24.
A hedge fund recently raised its stake in Amedica stock. Vanguard Group Inc. raised its holdings in Amedica Co. (NASDAQ:AMDA) by 7.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 595,866 shares of the medical equipment provider’s stock after buying an additional 39,603 shares during the quarter. Vanguard Group Inc. owned about 2.26% of Amedica worth $226,000 at the end of the most recent reporting period. 63.60% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Amedica (AMDA) Downgraded by ValuEngine” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/12/04/amedica-amda-downgraded-by-valuengine.html.
Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Amedica Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amedica Co. and related companies.